Targeted modulation of MGMT: Clinical implications

被引：193

作者：

Liu, LL ^{[1
]}

Gerson, SL ^{[1
]}

机构：

[1] Case Western Reserve Univ, Case Comprehens Care Ctr, Dept Med, Div Hematol Oncol, Cleveland, OH 44106 USA

来源：

CLINICAL CANCER RESEARCH | 2006年 / 12卷 / 02期

关键词：

D O I：

10.1158/1078-0432.CCR-05-2543

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

O-6-Methylguanine DNA methyltransferase (MGMT) has been studied for >20 years as a gene that is associated with the mulagenicity and cytotoxicity induced by either methylating carcinogens or alkylating (methylating and chloroethylating) therapeutic agents. Pioneering studies of alkylating agents identified alkylated guanine at the O-6 position, the substrate of MGMT, as a potentially promutagenic and lethal toxic DNA lesion. MGMT plays a prominent role in DNA adduct repair that limits the mutagenic and cytotoxic effect of alkylating agents. Because of its role in cancer etiology and chemotherapy resistance, MGMT is of particular interest. In this article, the clinical effect of MGMT expression and targeted modulation of MGMT will be summarized.

引用

页码：328 / 331

页数：4

共 40 条

[1]

Bacolod MD, 2004, MOL CANCER THER, V3, P1127

[2]

Belinsky SA, 2002, CANCER RES, V62, P2370

[3] Unmasking a killer:: DNA O6-methylguanine and the cytotoxicity of methylating agents [J].